The global softgel capsules market was valued at USD 7.87 billion in 2025 and is projected to grow from USD 8.32 billion in 2026 to USD 13.46 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.20% over the forecast period. North America led the market in 2025, holding a 35.58% share. The steady climb in valuation reflects consistent demand from both the pharmaceutical and nutraceutical sectors, which increasingly rely on softgels as a convenient and stable dosage format.

Why the Market Is Growing

Softgel capsules serve both nutraceutical and cosmetic industries by offering a convenient, easy-to-swallow, formulation-friendly dosage form, and they are widely used for oils, lipid-based ingredients, vitamins, specialty actives, and drugs that need improved absorption and stability. Growing consumer preference for preventive healthcare and branded wellness supplements is pushing manufacturers toward higher-quality encapsulation, while pharmaceutical companies continue turning to softgels to boost bioavailability, differentiate products, and improve patient compliance. Together, these forces are driving investment in expanded manufacturing capacity and new delivery innovations.

One notable trend is the growing use of softgels specifically to overcome bioavailability challenges. Many pharmaceutical and nutraceutical ingredients suffer from poor water solubility, which limits how well the body absorbs them, and softgel capsules address this by delivering active ingredients in a pre-dissolved or lipid-based form that supports faster release and better performance.

Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/softgel-capsules-market-103353

Key Drivers, Restraints, Opportunities, and Challenges

Driver: Rising consumption of vitamins, omega-3 supplements, herbal extracts, immunity products, and beauty-from-within formulations is fueling demand, since softgels suit liquid or oil-based ingredients and help improve consumer adherence.

Restraint: Softgels are highly sensitive to formulation balance, shell composition, and storage conditions, so poor interaction between shell and fill material can cause leakage, shell deformation, cross-linking, and reduced dissolution — problems that worsen under high heat and humidity and push up manufacturing costs through tighter quality controls.

Opportunity: Rising interest in plant-based lifestyles and religious or ethical restrictions on animal-derived ingredients is pushing manufacturers to invest in non-animal, plant-based softgel technologies, opening room for product differentiation aimed at vegan and premium consumers.

Challenge: Softgel production depends heavily on gelatin and other specialty inputs, and fluctuating prices or supply-chain disruptions raise costs and squeeze margins, compounded by the rigorous environmental controls softgel manufacturing requires.

Market Segmentation

By type: the market splits into gelatin capsules and non-animal softgel capsules (starches, pullulan, and others), with gelatin capsules dominating thanks to established processes, strong compatibility with oil- and liquid-based fills, and easier large-scale manufacturing. The non-animal segment, meanwhile, is projected to grow faster, at a 7.54% CAGR.

By application: segments include prescription medicines, OTC, and nutraceuticals, with prescription medicines holding the largest share since many prescription drugs need accurate dosing and improved bioavailability that softgels can deliver. The nutraceutical segment is expected to grow at a 7.60% CAGR.

By manufacturer type: the market is divided among pharmaceutical companies, nutraceutical companies, and others, with pharmaceutical companies leading due to stronger regulatory capabilities and larger commercial drug portfolios.

Regional Snapshot

• North America: reached USD 2.80 billion in 2025, remaining the top region, supported by an already well-established base of supplement users in the U.S.
• Europe: projected to grow at 5.64% CAGR and reach USD 2.53 billion by 2026, aided by an aging population's rising use of easy-to-administer medicines and daily supplements.
• Asia Pacific: estimated at USD 1.83 billion in 2026, driven by rising incomes, urbanization, and growing health awareness.
• U.S.: estimated at USD 2.69 billion in 2026, about 32.36% of the global market.
• Japan: estimated at USD 0.44 billion in 2026, roughly 5.24% of the global total.

Competitive Landscape

The market is highly consolidated, led by players such as Lonza, Sirio Pharma, Catalent Inc, Hunan Er Kang Pharmaceutical Co., Ltd, Aenova Group GmbH, Fuji Capsule Co., Ltd., Delpharm, and Captek Softgel International Inc., with strategic partnerships, new product launches, and R&D investment driving competitive gains. Recent industry moves highlight this momentum: Robinson Pharma expanded its manufacturing capabilities in mid-2025 with a new high-speed liquid production line, while Caldic and Lonza Capsugel entered an exclusive North American distribution partnership in October 2025 to showcase new nutraceutical applications.

Outlook

The report frames the market's expansion around rising healthcare demand, growing nutraceutical and dietary-supplement consumption, and increasing preference for convenient oral drug-delivery systems, alongside continued innovation in gelatin and plant-based capsule technologies. With a projected doubling in value between 2025 and 2034, softgel capsules are set to remain a core dosage format across pharmaceutical, nutraceutical, and cosmeceutical applications.